367 related articles for article (PubMed ID: 17080381)
41. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
[TBL] [Abstract][Full Text] [Related]
42. Hospital cross-transmission of extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae.
Cholley P; Thouverez M; Gbaguidi-Haore H; Sauget M; Slekovec C; Bertrand X; Talon D; Hocquet D
Med Mal Infect; 2013 Aug; 43(8):331-6. PubMed ID: 23876202
[TBL] [Abstract][Full Text] [Related]
43. [Mortality risk factors for bloodstream infections caused by extended-spectrum beta-lactamase-producing microorganisms].
Ferrández O; Grau S; Saballs P; Luque S; Terradas R; Salas E
Rev Clin Esp; 2011 Mar; 211(3):119-26. PubMed ID: 21371702
[TBL] [Abstract][Full Text] [Related]
44. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Lautenbach E; Strom BL; Bilker WB; Patel JB; Edelstein PH; Fishman NO
Clin Infect Dis; 2001 Oct; 33(8):1288-94. PubMed ID: 11565067
[TBL] [Abstract][Full Text] [Related]
45. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
[TBL] [Abstract][Full Text] [Related]
46. Extended spectrum beta-lactamases in Escherichia coli & Klebsiella pneumoniae & associated risk factors.
Goyal A; Prasad KN; Prasad A; Gupta S; Ghoshal U; Ayyagari A
Indian J Med Res; 2009 Jun; 129(6):695-700. PubMed ID: 19692752
[TBL] [Abstract][Full Text] [Related]
47. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections.
Lee SY; Kuti JL; Nicolau DP
J Infect; 2007 May; 54(5):463-8. PubMed ID: 17067681
[TBL] [Abstract][Full Text] [Related]
48. Clinical and molecular epidemiology of healthcare-associated infections due to extended-spectrum beta-lactamase (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae that harbor multiple ESBL genes.
Apisarnthanarak A; Kiratisin P; Mundy LM
Infect Control Hosp Epidemiol; 2008 Nov; 29(11):1026-34. PubMed ID: 18947321
[TBL] [Abstract][Full Text] [Related]
49. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
Akyar I
Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
[TBL] [Abstract][Full Text] [Related]
50. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
[TBL] [Abstract][Full Text] [Related]
51. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study.
Peralta G; Lamelo M; Alvarez-García P; Velasco M; Delgado A; Horcajada JP; Montero M; Roiz MP; Fariñas MC; Alonso J; Martínez LM; Gutiérrez-Macías A; Alava JA; Rodríguez A; Fleites A; Navarro V; Sirvent E; Capdevila JA;
BMC Infect Dis; 2012 Oct; 12():245. PubMed ID: 23038999
[TBL] [Abstract][Full Text] [Related]
52. Urinary tract infections owing to ESBL-producing bacteria: microorganisms change--clinical pattern does not.
Özçakar ZB; Yalçınkaya F; Kavaz A; Kadıoğlu G; Elhan AH; Aysev D; Güriz H; Ekim M
Acta Paediatr; 2011 Aug; 100(8):e61-4. PubMed ID: 21392102
[TBL] [Abstract][Full Text] [Related]
53. Investigation of risk factors for community-acquired urinary tract infections caused by extended-spectrum beta-lactamase
Koksal E; Tulek N; Sonmezer MC; Temocin F; Bulut C; Hatipoglu C; Erdinc FS; Ertem G
Investig Clin Urol; 2019 Jan; 60(1):46-53. PubMed ID: 30637361
[TBL] [Abstract][Full Text] [Related]
54. Wide dissemination of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. in acute care and rehabilitation hospitals.
Kohlenberg A; Schwab F; Rüden H
Epidemiol Infect; 2012 Mar; 140(3):528-34. PubMed ID: 21676355
[TBL] [Abstract][Full Text] [Related]
55. Clinical characteristics of urosepsis caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumonia and their emergence in the community.
Lee JC; Lee NY; Lee HC; Huang WH; Tsui KC; Chang CM; Lee CC; Chen PL; Wu CJ; Hsueh PR; Ko WC
J Microbiol Immunol Infect; 2012 Apr; 45(2):127-33. PubMed ID: 22041167
[TBL] [Abstract][Full Text] [Related]
56. Epidemiology and outcome of bacteremia caused by extended spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. in a tertiary care teaching hospital in south India.
Abhilash KP; Veeraraghavan B; Abraham OC
J Assoc Physicians India; 2010 Dec; 58 Suppl():13-7. PubMed ID: 21563608
[TBL] [Abstract][Full Text] [Related]
57. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia.
Ben-Chetrit E; Eldaim MA; Bar-Meir M; Dodin M; Katz DE
Int J Antimicrob Agents; 2019 Apr; 53(4):423-428. PubMed ID: 30572008
[TBL] [Abstract][Full Text] [Related]
58. Risk factors for and outcomes of healthcare-associated infection due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae in Thailand.
Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
Infect Control Hosp Epidemiol; 2007 Jul; 28(7):873-6. PubMed ID: 17564993
[TBL] [Abstract][Full Text] [Related]
59. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.
Joo EJ; Park DA; Lee NR; Moon SY; Choi JK; Ko JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2093-2100. PubMed ID: 28643188
[TBL] [Abstract][Full Text] [Related]
60. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon.
Kanafani ZA; Mehio-Sibai A; Araj GF; Kanaan M; Kanj SS
Am J Infect Control; 2005 Aug; 33(6):326-32. PubMed ID: 16061138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
